Royce & Associates LP acquired a new stake in Tempus AI, Inc. (NASDAQ:TEM – Free Report) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 112,574 shares of the company’s stock, valued at approximately $9,220,000. Royce & Associates LP owned about 0.06% of Tempus AI at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of the stock. Eagle Health Investments LP acquired a new stake in Tempus AI during the first quarter worth approximately $11,588,000. Aristotle Atlantic Partners LLC acquired a new position in shares of Tempus AI in the first quarter valued at approximately $6,179,000. Headlands Technologies LLC acquired a new position in shares of Tempus AI in the second quarter valued at approximately $2,689,000. Odyssean LLC bought a new position in shares of Tempus AI during the second quarter worth approximately $897,000. Finally, Fagan Associates Inc. bought a new position in shares of Tempus AI during the third quarter worth approximately $5,265,000. 24.22% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several analysts recently weighed in on TEM shares. Stifel Nicolaus dropped their price target on Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a report on Monday, August 3rd. Rothschild & Co Redburn initiated coverage on Tempus AI in a research note on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 price target for the company. Cantor Fitzgerald upped their price objective on Tempus AI from $80.00 to $92.00 and gave the company an “overweight” rating in a report on Tuesday, November 3rd. Roth Capital assumed coverage on Tempus AI in a research report on Tuesday, September 8th. They set a “neutral” rating and a $67.00 price objective on the stock. Finally, Canaccord Genuity Group increased their price objective on Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Eleven equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $79.37.
Read Our Latest Stock Report on Tempus AI
Insiders Place Their Bets
In related news, CEO Eric Lefkofsky sold 250,000 shares of the stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $70.36, for a total transaction of $17,590,000.00. Following the sale, the chief executive officer owned 50,000 shares of the company’s stock, valued at $3,518,000. This represents a 83.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Ryan Bartolucci sold 7,062 shares of the stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $75.00, for a total value of $529,650.00. Following the sale, the chief accounting officer directly owned 60,804 shares in the company, valued at $4,560,300. This represents a 10.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 978,449 shares of company stock valued at $72,226,961 in the last quarter. Company insiders own 24.26% of the company’s stock.
Tempus AI Stock Performance
NASDAQ TEM opened at $63.43 on Wednesday. The company has a quick ratio of 2.48, a current ratio of 2.61 and a debt-to-equity ratio of 2.70. The company has a market capitalization of $11.57 billion, a P/E ratio of -59.84 and a beta of 3.61. Tempus AI, Inc. has a 12-month low of $40.77 and a 12-month high of $89.09. The firm has a 50-day moving average price of $72.82 and a two-hundred day moving average price of $57.54.
Tempus AI (NASDAQ:TEM – Get Free Report) last announced its earnings results on Monday, November 2nd. The company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.16. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 47.00%. The company had revenue of $411.54 million for the quarter, compared to analysts’ expectations of $409.39 million. During the same period last year, the firm earned ($0.46) earnings per share. The business’s revenue for the quarter was up 23.1% on a year-over-year basis. Analysts anticipate that Tempus AI, Inc. will post -1.20 earnings per share for the current year.
About Tempus AI
Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.
Further Reading
- Five stocks we like better than Tempus AI
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
